Sparta Commercial Services (SRCO) 10-Q 25 Mar 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Jan. 31, 2024	Mar. 25, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jan. 31, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--04-30
Entity File Number	0-9483
Entity Registrant Name	SPARTA COMMERCIAL SERVICES, INC.
Entity Central Index Key	0000318299
Entity Tax Identification Number	30-0298178
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	555 Fifth Avenue
Entity Address, Address Line Two	14th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	(212)
Local Phone Number	239-2666
Title of 12(b) Security	Common stock, $.001 par value
Trading Symbol	SRCO
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		29,495,189

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jan. 31, 2024	Apr. 30, 2023
Current Assets
Cash and cash equivalents	$ 5,417	$ 4,028
Accounts receivable	2,890
Inventory	3,831
Other current assets
Total Current Assets	12,138	4,028
Property and equipment, net of accumulated depreciation and amortization of $213,262 and $213,262, respectively
Deposits - rent deposit	9,000	9,000
Total assets	21,138	13,028
Current Liabilities
Bank overdraft		54,410
Short Term Loan	216,585	1,585
Accounts payable and accrued expenses	1,587,488	1,698,457
Derivative liabilities	1,042,955	1,375,767
Current portion notes payable	6,946,644	6,694,245
Deferred revenue
Total Current Liabilities	9,793,673	9,824,464
Total Long Term Liabilities	529,294	435,753
Total liabilities	10,322,967	10,260,217
Stockholders’ Deficit:
Common stock, $0.001 par value; 750,000,000 shares authorized, and 26,141,106 and 23,045,205 shares issued and outstanding, respectively	26,141	23,045
Common stock to be issued 2,669,956 and 23,704,788 respectively	26,322	23,705
Additional paid-in-capital	55,533,691	54,872,206
Accumulated deficit	(66,880,291)	(66,150,857)
Total deficiency in stockholders’ equity	(11,279,318)	(11,216,484)
Non-controlling interest	977,489	969,295
Total Deficit	(10,301,828)	(10,247,189)
Total Liabilities and Deficit	21,138	13,028
Series A Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	12,500	12,500
Series C Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	1,919	1,979
Series D Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	401	938
Related Party [Member]
Current Liabilities
Loans payable-related parties	$ 529,294	$ 435,753

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jan. 31, 2024	Apr. 30, 2023
Property and equipment, net of accumulated depreciation and amortization	$ 213,262	$ 213,262
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	10,000,000	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock shares issued	26,141,106	23,045,205
Common stock shares outstanding	26,141,106	23,045,205
Common stock to be issued	2,669,956	23,704,788
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares designated	35,850	35,850
Preferred stock, shares issued	125	125
Preferred stock, shares outstanding	125	125
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	4,200,000	4,200,000
Preferred stock, shares issued	1,979,157	2,363,000
Preferred stock, shares outstanding	1,979,157	2,363,000
Preferred stock, liquidation and redemption value per share	$ 1	$ 1
Series D Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	2,000,000	2,000,000
Preferred stock, shares issued	937,754	618,411
Preferred stock, shares outstanding	937,754	618,411
Preferred stock, liquidation and redemption value per share	$ 1	$ 1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Revenue
Total Revenue	$ 36,736	$ 63,670	$ 151,433	$ 189,042
Less Cost of goods sold	8,010	9,142	31,218	31,987
Gross profit	28,725	54,528	120,363	157,055
Operating expenses:
Compensation and Related Cost	128,229	248,614	428,021	594,300
Consulting Fee	15,780	22,611	50,670	356,001
Rent and lease	18,000	17,100	54,000	49,700
Accounting and Legal	6,271	19,763	51,921	42,763
General and administrative	105,222	95,607	308,773	238,659
Research and Development
Total operating expenses	273,503	403,695	893,386	1,281,423
Loss from operations	(244,778)	(349,167)	(773,023)	(1,124,368)
Other Income ( expense)
Commission on municipal bonds	8,680	473	12,577	473
Financing cost	(155,439)	2,305	(440,307)
Write off convertible notes and bad debt	85,912	(324,970)	146,701	625,064
Gain (loss) in changes in fair value of derivative liability	155,439	1,757,044	332,812	5,044,879
Total other (income) expense	94,592	1,434,852	51,783	5,670,416
Net income (loss)	(150,186)	1,085,685	(721,240)	4,546,048
Net profit attributable to minority shareholder	(3,514)	(3,080)	(8,195)	(9,794)
Preferred dividend
Net income (loss) attributed to common stockholders	$ (153,699)	$ 1,082,605	$ (729,434)	$ 4,536,254
Basic and diluted loss per share:
Loss from continuing operations attributable to Sparta Commercial Services, Inc. common stockholders, basic
Loss from continuing operations attributable to Sparta Commercial Services, Inc. common stockholders, diluted
Net loss attributable to Sparta Commercial Services, Inc. common stockholders, basic	(0.01)	(0.05)	(0.04)	0.25
Net loss attributable to Sparta Commercial Services, Inc. common stockholders, diluted	$ (0.01)	$ (0.05)	$ (0.04)	$ 0.25
Weighted average shares outstanding, basic	25,432,999	19,686,822	18,074,511	18,074,511
Weighted average shares outstanding, diluted	25,432,999	19,686,822	18,074,511	18,074,511
Information technology [Member]
Revenue
Total Revenue	$ 30,071	$ 60,120	$ 128,142	$ 173,559
New World Health [Member]
Revenue
Total Revenue	$ 6,665	$ 3,550	$ 23,291	$ 15,483

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholder's Deficits - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Series D Preferred Stock [Member]	Common Stock [Member]	Common Stock to be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Apr. 30, 2022	$ 12,500	$ 2,363	$ 618	$ 15,128	$ 8,292	$ 53,210,921	$ (73,984,686)	$ 984,175	$ (19,750,689)
Balance, shares at Apr. 30, 2022	125	2,163,000	618,411	15,128,005	8,916,805
Conversion of notes to common shares
Issuance of common shares for cash					$ 1,824	93,175			94,999
Issuance of stock for services, shares					1,824,771
Shares issued for services				$ (1,595)		(243,786)			(245,381)
Conversion of Preferred to common shares		$ (60)		60		9,940			9,940
Net loss for the quarter							1,101,351	3,924	1,105,275
Issuance of stock for services				1,595		243,786			245,381
Issuance of preferred shares
Issuance of shares for equity				518		44,128			44,646
Balance at Jul. 31, 2022	$ 12,500	$ 2,303	$ 618	$ 17,301	$ 10,116	53,601,950	(72,883,335)	988,099	(18,250,448)
Balance, shares at Jul. 31, 2022	125	2,103,000	618,411	17,301,298	10,741,576
Balance at Apr. 30, 2022	$ 12,500	$ 2,363	$ 618	$ 15,128	$ 8,292	53,210,921	(73,984,686)	984,175	(19,750,689)
Balance, shares at Apr. 30, 2022	125	2,163,000	618,411	15,128,005	8,916,805
Balance at Jan. 31, 2023	$ 12,500	$ 1,979	$ 938	$ 21,113	$ 23,334	54,570,072	(70,684,736)	994,402	(15,060,398)
Balance, shares at Jan. 31, 2023	125	1,979,157	937,754	21,581,449	23,333,438
Balance at Apr. 30, 2022	$ 12,500	$ 2,363	$ 618	$ 15,128	$ 8,292	53,210,921	(73,984,686)	984,175	(19,750,689)
Balance, shares at Apr. 30, 2022	125	2,163,000	618,411	15,128,005	8,916,805
Issuance of shares for services, shares				1,594,960
Conversion of Preferred to common shares, shares		(60,000)		60,000
Issuance of shares for equity, shares				518,333
Balance at Jul. 31, 2023	$ 12,500	$ 1,979	$ 938	$ 23,951	$ 24,007	55,052,142	(66,362,200)	972,004	(10,274,679)
Balance, shares at Jul. 31, 2023	125	1,979,157	937,701	23,951,111	24,006,882
Balance at Jul. 31, 2022	$ 12,500	$ 2,303	$ 618	$ 17,301	$ 10,116	53,601,950	(72,883,335)	988,099	(18,250,448)
Balance, shares at Jul. 31, 2022	125	2,103,000	618,411	17,301,298	10,741,576
Net loss for the quarter							2,352,298	2,789	2,355,087
Issuance of shares for equity				$ 330		24,670			25,000
Issuance of shares for equity, shares				330,179
Conversion of Preferred to common shares C		$ (581)		$ 581		96,915			96,915
Conversion of Preferred to common shares C, shares		(581,000)		581,000
Conversion of Preferred to common shares D			$ (141)	$ 141		141,053			141,053
Conversion of Preferred to common shares D, shares			(141,000)	141,000
Stocks issued as note holder incentive				$ 213		19,388			19,601
Stocks issued as note holder incentive, shares				212,500
Issuance of common shares for cash				$ 135	506	49,359			50,000
Issuance of common shares for cash, shares				134,805
Balance at Oct. 31, 2022	$ 12,500	$ 1,722	$ 477	$ 18,701	$ 10,622	53,933,335	(70,531,037)	990,888	(15,562,792)
Balance, shares at Oct. 31, 2022	125	1,522,000	477,411	18,700,782	11,247,437
Issuance of stock for services, shares				333,939
Shares issued for services				$ (334)		(37,261)			(37,595)
Net loss for the quarter							(153,699)	3,514	(150,186)
Issuance of stock for services				334		37,261			37,595
Issuance of shares for equity				$ 952		83,098			84,050
Issuance of shares for equity, shares				952,036
Conversion of preferred shares		$ (1,922)		$ 747	$ 1,175.10	190,103			190,103
Conversion of preferred shares, shares		(1,922,101)		747,000	1,175,101
Issuance for Notes payable				$ 379		34,160			34,539
Issuance for Notes payable, shares				378,909
Adjustment		$ 2,179	$ 461		$ 11,537	292,115			306,292
Adjustment, shares		2,379,258	460,343	468,783	10,910,900
Balance at Jan. 31, 2023	$ 12,500	$ 1,979	$ 938	$ 21,113	$ 23,334	54,570,072	(70,684,736)	994,402	(15,060,398)
Balance, shares at Jan. 31, 2023	125	1,979,157	937,754	21,581,449	23,333,438
Balance at Apr. 30, 2023	$ 12,500	$ 1,979	$ 938	$ 23,045	$ 23,705	54,872,206	(66,150,857)	969,295	(10,247,189)
Balance, shares at Apr. 30, 2023	125	1,979,157	937,701	23,045,205	23,704,788
Issuance of Preferred and Common Stock for Cash					$ 1,133	103,867			105,000
Issuance of Preferred and Common Stock for Cash, shares					1,133,000
Conversion of notes to common shares				$ 75		6,900			6,975
Conversion of notes to common shares, shares				75,000
Issuance of common shares for cash				$ 831	$ (831)	69,169		2,709	71,878
Issuance of stock for services, shares				830,906	(830,906)
Shares issued for services							(211,343)		(211,343)
Conversion of Preferred to common shares
Preferred dividend
Net loss for the quarter
Issuance of stock for services							211,343		211,343
Balance at Jul. 31, 2023	$ 12,500	$ 1,979	$ 938	$ 23,951	$ 24,007	55,052,142	(66,362,200)	972,004	(10,274,679)
Balance, shares at Jul. 31, 2023	125	1,979,157	937,701	23,951,111	24,006,882
Balance at Apr. 30, 2023	$ 12,500	$ 1,979	$ 938	$ 23,045	$ 23,705	54,872,206	(66,150,857)	969,295	(10,247,189)
Balance, shares at Apr. 30, 2023	125	1,979,157	937,701	23,045,205	23,704,788
Balance at Jan. 31, 2024	$ 12,500	$ 1,919	$ 401	$ 26,141	$ 26,322	55,533,691	(66,880,291)	977,490	(10,301,828)
Balance, shares at Jan. 31, 2024	125	1,979,157	937,701	26,141,106	25,587,887
Balance at Jul. 31, 2023	$ 12,500	$ 1,979	$ 938	$ 23,951	$ 24,007	55,052,142	(66,362,200)	972,004	(10,274,679)
Balance, shares at Jul. 31, 2023	125	1,979,157	937,701	23,951,111	24,006,882
Issuance of Preferred and Common Stock for Cash					$ 988	64,012			65,000
Issuance of Preferred and Common Stock for Cash, shares					988,000
Issuance of common shares for cash				$ 25		3,850			3,875
Issuance of stock for services, shares				25,000
Preferred dividend				$ 347	$ (347)	24,653			24,653
Net loss for the quarter							(364,392)	1,972	(362,420)
Stocks issued as a note holder incentive					$ 54	4,946			5,000
Stocks issued as a note holder incentive, shares					54,000
Preferred dividend, shares				346,995	(346,995)
Balance at Oct. 31, 2023	$ 12,500	$ 1,979	$ 938	$ 24,323	$ 24,702	55,149,603	(66,726,592)	973,976	(10,538,571)
Balance, shares at Oct. 31, 2023	125	1,979,157	937,701	24,323,106	24,701,887
Shares issued for services				$ (151)		(23,340)			(23,491)
Net loss for the quarter							(155,699)	3,514	(150,186)
Conversion of notes payables				$ 900	$ 886	303,653			305,439
Conversion of notes payables, shares				900,000	886,000
Conversion of preferred shares		(60)	(537)	$ 767	$ (170)
Conversion of preferred shares, shares				767,000
Issuance of stock for services				$ 151		23,340			23,491
Issuance of shares for services, shares				151,000
Issuance for cash received					904	57,095			57,999
Balance at Jan. 31, 2024	$ 12,500	$ 1,919	$ 401	$ 26,141	$ 26,322	$ 55,533,691	$ (66,880,291)	$ 977,490	$ (10,301,828)
Balance, shares at Jan. 31, 2024	125	1,979,157	937,701	26,141,106	25,587,887

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income ( loss )	$ (721,240)	$ 4,546,048
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Loss (Gain) from change in fair value of derivative liabilities	332,812	(5,044,879)
Amortization of debt discount
Non-cash financing cost
Non-cash consulting fees		2,480
Write off promissory notes		(625,064)
Changes in operating assets and liabilities
Accounts receivable	(2,890)	(2,168)
Inventory	(3,831)	3,166
Accounts payable and accrued expenses	(110,969)	78,215
Deferred revenue		(5,348)
Net cash used in operating activities	(506,118)	(1,047,550)
CASH FLOWS FROM INVESTING ACTIVITIES:
CASH FLOWS FROM FINANCING ACTIVITIES
Bank overdraft	(54,410)	13,895
Proceeds from sale of stock	293,000	135,000
Proceeds from notes payable	254,000
Proceeds from related party notes		(37,650)
Payments on related party notes
Net adjustments /conversion of promissory notes	31,307	936,600
Net cash provided by financing activities	523,897	1,047,845
Net (decrease) increase in cash	17,779	295
Cash and cash equivalents, beginning of period	4,028	317
Cash and cash equivalents, end of period	21,807	612
Cash paid for:
Interest
Income taxes

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Jan. 31, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying unaudited condensed consolidated financial statements follows. Business General Overview Sparta Commercial Services, Inc. (“Sparta,” “we,” “us,” or the “Company”) is a Nevada corporation with headquarters in New York City. We are a multi-disciplined parent corporation operating across three business sectors – Financial Services, E-Commerce & Mobile Technology, and Health and Wellness. Sparta’s historic roots were in the Powersports industry until the financial crisis that began 2008. The Company provided consumer retail installment loans and leases through authorized motorcycle dealerships in 33 states, with financing lines of credit provided by institutional lenders. In 2007, the Company introduced a Municipal Financing program which has financed over 100 jurisdictions to date. Vehicle History Reports are a staple of Sparta’s E-Commerce Technology subsidiary iMobile Solutions, Inc. Whether a vehicle is intended for personal, business or recreational use, Sparta’s Vehicle History Reports are highly regarded for accuracy and completeness and have been sold across all 50 states and in 62 countries worldwide. With iMobile App, the Company additionally provides mobile technology services, including web and mobile application creation, development and management, text messaging services, CRM (Customer Relationship Management) tools, and custom kitchen ordering systems for a wide range of businesses to increase revenue, build brand recognition, and improve customer engagement. Sparta’s subsidiary, New World Health Brands, Inc., offers high quality dietary supplements. Sparta’s subsidiary, Sparta Crypto, Inc., is in the process of completing a proprietary state-of-the-art platform designed to connect users of widely adopted digital currencies with sellers of various goods and services; and has completed and tested a cryptocurrency payment gateway called SpartaPayIQ. Agoge Global USA, Inc. (“Agoge”) was formed as a subsidiary of Sparta Crypto, Inc. in December 2022 and entered into a Joint Venture Agreement with WeDev Group of Brazil to facilitate cross-border transactions between importers and exporters of goods from the U.S. and Brazil and is expected to launch in last fiscal quarter of 2024 Basis of Presentation The accompanying unaudited condensed consolidated financial statements as of January 31, 2024 and for the nine months ended January 31, 2024 and 2023 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission, including Form 10-Q and Regulation S-K. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments), which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. The Company believes that the disclosures provided are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and explanatory notes for the year ended April 30, 2023 as disclosed in the Company’s Form 10-K for that year as filed with the Securities and Exchange Commission on August 15, 2023. The results of operations for the nine months ended January 31, 2024 are not necessarily indicative of the results to be expected for any other interim period or the full year ending April 30, 2024. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The third-party ownership of the Company’s subsidiary is accounted for as noncontrolling interest in the consolidated financial statements. Changes in the noncontrolling interest are reported in the statement of changes in deficit. Estimates These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosures of revenues and expenses for the said period. Accordingly, actual results could differ from those estimates. Revenue Recognition During the first quarter of 2018, the Company adopted A.S.U. 2014-09, Revenue from Contracts with Customers (Topic 606) The Company acts as a principal in its revenue transactions as it is the primary obligor. SCHEDULE OF DISAGGREGATION REVENUE 3-months ended 9-months ended Revenue Jan 2024 Jan 2023 Jan 2024 Jan 2023 Information technology $ 30,071 $ 60,120 $ 128,142 $ 173,559 New World Health $ 6,665 $ 3,550 $ 23,291 $ 15,483 Total 36,736 63,670 151,433 189,042 Revenues from mobile app products and New World Health Brands products are generally recognized upon delivery. Revenues from History Reports are typically recognized upon delivery/download. Prepayments received from customers before delivery (if any) are recognized as deferred revenue and recognized upon delivery. The Company records deferred revenues when cash payments are received or due before our performance, including refundable amounts. Cash Equivalents All liquid investments with three months or less maturity are cash equivalents for the accompanying financial statements. Fair Value Measurements The Company has adopted ASC 820, “Fair Value Measurements .” ● Level 1 — ● Level 2 — ● Level 3 — This hierarchy requires the Company to use observable market data when available and to minimize the use of unobservable inputs when determining fair value. Observable inputs may not always be available for some products or in certain market conditions. Income Taxes We utilize ASC 740, “ Income Taxes The Company recognizes the impact of a position in the financial statements only if that position is more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position. Our practice recognizes interest or penalties related to income tax matters in income tax expense. Stock-Based Compensation We account for our stock-based compensation under ASC 718 “ Compensation–Stock Compensation We use the fair value method for equity instruments granted to non-employees and the Black-Scholes model to measure options’ fair value. The stock-based fair value compensation is determined as of the date of the grant or at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. Inventories The Company’s inventories represent finished goods, consisting of available products. They are accounted for using the first-in, first-out (FIFO) method and valued at the lower of cost or net realizable value. Inventory consists of finished goods for the Company’s New World Health business. Property and Equipment Property and equipment are recorded at cost. Minor additions and renewals are expensed in the year incurred. Significant additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is calculated using the straight-line method over the estimated useful lives. The estimated useful lives of significant depreciable assets are as follows: SCHEDULE OF ESTIMATED USEFUL OF PROPERTY AND EQUIPMENT Leasehold improvements 3 years Furniture and fixtures 7 years Website costs 3 years Computer Equipment 5 years Estimated Useful of Property and Equipment 5 years Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents, and receivables. The Company places its cash and temporary cash investments with high-credit quality institutions. At times, such investments may be more than the FDIC insurance limit. Net Loss Per Share The Company uses ASC 260-10, “ Earnings Per Share Derivative Liabilities The Company assessed the classification of its derivative financial instruments as of January 31, 2024, and April 30, 2024, which consist of convertible instruments and rights to shares of the Company’s common stock. It determined that such derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed conventional, as described. Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “ Accounting for Derivative Instruments and Hedging Activities The Company assessed the classification of its derivative financial instruments as of January 31, 2024 and April 30, 2023, which consist of convertible instruments and rights to shares of the Company’s common stock and determined that such derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described. Reclassifications Certain reclassifications have been made to conform with prior periods’ data to the current presentation. These reclassifications did not affect reported losses. Recent Accounting Pronouncements- No recent pronouncements have been made or adopted in the quarter ended January 31, 2024. All of the pronouncements that affect our business have been adopted.

GOING CONCERN MATTERS

GOING CONCERN MATTERS	9 Months Ended
	Jan. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN MATTERS	NOTE B – GOING CONCERN MATTERS The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed consolidated financial statements, the Company has incurred recurring losses and generated negative cash flows from operating activities since inception. As of January 31, 2024, the Company had an accumulated deficit of $ 66,880,291 10,301,828 The Company’s existence is dependent upon management’s ability to develop profitable operations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the Company’s efforts will be successful. No assurance can be given that management’s actions will result in profitable operations or the resolution of its liquidity problems. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern. In order to improve the Company’s liquidity, the Company’s management is actively pursuing additional equity financing through discussions with investment bankers and private investors. There can be no assurance that the Company will be successful in its effort to secure additional equity financing. The Company’s existence depends on management’s ability to develop profitable operations. Management is devoting substantially all its efforts to growing its business and raising capital, and there can be no assurance that the Company’s efforts will be successful. The management’s actions are not guaranteed to result in profitable operations or resolve liquidity problems. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company’s management actively pursues additional equity financing through discussions with investment bankers and private investors. There can be no assurance that the Company will be successful in its effort to secure additional equity financing.

NOTES PAYABLE AND DERIVATIVES

NOTES PAYABLE AND DERIVATIVES	9 Months Ended
	Jan. 31, 2024
Debt Disclosure [Abstract]
NOTES PAYABLE AND DERIVATIVES	NOTE C – NOTES PAYABLE AND DERIVATIVES The Company has numerous outstanding notes payable to various parties. The notes bear interest at rates of 5 20 SCHEDULE OF NOTES PAYABLE Notes Payable January 31, 2024 April 30, 2023 Notes convertible at holder’s option $ 2,313,697 $ 3,112,734 Notes convertible at Company’s option 335,700 335,700 Non-convertible notes payable 2,438,308 1,861,650 Subtotal 5,087,705 5,310,084 Total $ 5,087,705 $ 5,310,084 The balance of accrued interest of the above notes as of January 31, 2024, and April 30, 2023, were 1,651,532 1,508,934 142,598 Certain notes payable contain variable conversion rates, and the conversion features are classified as derivative liabilities. The conversion prices are based on the market price of the Company’s common stock, at discounts of 30 48 The Company’s derivative financial instruments are embedded derivatives related to the outstanding short-term Convertible Notes Payable. These embedded derivatives included certain conversion features indexed to the Company’s common stock. The accounting treatment of derivative financial instruments requires that the Company record the derivatives and related items at their fair values as of the inception date of the Convertible Notes Payable and at fair value as of each subsequent balance sheet date. In addition, under the provisions of Accounting Standards Codification subtopic 815-40, Derivatives and Hedging; Contracts in Entity’s Own Equity (“ASC 815-40”), as a result of entering into the Convertible Notes Payable, the Company is required to classify all other non-employee stock options and warrants as derivative liabilities and mark them to market at each reporting date. Any change in fair value, including modifications of terms, will be recorded as non-operating, non-cash income, or expense at each reporting date. If the fair value of the derivatives is higher at the subsequent balance sheet date, the Company will record a non-operating, non-cash charge. If the fair value of the products is lower at the subsequent balance sheet date, the Company will record non-operating, non-cash income. These Notes are subject to a six-year Statute of Limitations in which to bring any potential claims. The change in fair value of the derivative liabilities on January 31, 2024, was calculated with the following average assumptions using a Black-Scholes option pricing model are as follows: SCHEDULE OF DERIVATIVE LIABILITIES ASSUMPTIONS USING BLACK-SCHOLES OPTION Significant Assumptions: Risk-free interest rate Ranging from 0.16 0.2 % Expected stock price volatility Ranging from 155 270 % Expected dividend payout 0 Expected life in years Ranging from 0.25 3.0 Expected life in years Ranging from 0.25 3.0 Changes in derivative liability during the three months ended January 31, 2024, and 2023 were: SCHEDULE OF CHANGES IN DERIVATIVE LIABILITIES January 31, January 31, 2024 2023 Balance, beginning of year $ 1,375,767 $ 9,549,640 Derivative liability extinguished (100,797 ) (336,418 ) Derivative financial liability arising on the issuance of convertible notes and warrants - Fair value adjustments (76,576 ) (4,168,344 ) Balance, end of period $ 1,198,394 $ 4,504,762

LOANS PAYABLE TO RELATED PARTIE

LOANS PAYABLE TO RELATED PARTIES	9 Months Ended
	Jan. 31, 2024
Related Party Transactions [Abstract]
LOANS PAYABLE TO RELATED PARTIES	NOTE D – LOANS PAYABLE TO RELATED PARTIES As of January 31, 2024, and April 30, 2023, aggregated loans and notes payable, without demand and with no interest, to officers, directors, and other related parties were $ 436,253 435,753

EQUITY TRANSACTIONS

EQUITY TRANSACTIONS	9 Months Ended
	Jan. 31, 2024
Equity [Abstract]
EQUITY TRANSACTIONS	NOTE E EQUITY TRANSACTIONS Preferred Stock The Company is authorized to issue 10,000,000 0.001 35,850 100 1,000 10,000 4,200,000 1.00 2,000,000 1 During the nine months ended January 31, 2024, the Company: ● Issued 1,349,005 107,000 ● Issued 153,864 48,490 ● Issued 75,000 6,975 ● Sold to eleven accredited investors 2,747,339 191,000 ● Issued 60,000 10,000 ● Issued 536,824 134,206 During the nine months ended January 31, 2023, the Company: ● Issued 1,388,376 231,396 ● Issued 564,212 141,053 Common Stock The Company is authorized to issue 750,000,000 0.001 26,141,106 23,045,205 During the nine months ended January 31, 2024, the Company: ● Issued 1,349,005 107,000 ● Issued 153,864 48,490 ● Issued 75,000 6,975 ● Sold to eleven accredited investors 2,747,339 191,000 ● Issued 60,000 10,000 ● Issued 536,824 134,206 During the nine months ended January 31, 2023, the Company: ● Sold 3,102,346 212,500 ● Issued 330,179 ● Issued 1,388,376 ● Issued 564,212 ● Issued 950,833 83,447 ● Issued 378,909 35,000 ● Issued 1,928,899 282,981 During the nine months ended January 31, 2023, the Company: Sold to six accredited investors 2,726,036 182,500

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Jan. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE F – FAIR VALUE MEASUREMENTS The Company follows the guidelines established according to ASC 820, which established a framework for measuring fair value and expands disclosure about fair value measurements. ASC 820 defines fair value as the amount received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes the following three levels of inputs that may be used: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs when there is little or no market data available, thereby requiring an entity to develop its own assumptions. The fair value hierarchy gives the lowest priority to Level 3 inputs. The table below summarizes the fair values of financial liabilities as of January 31, 2024: SCHEDULE OF FAIR VALUES OF FINANCIAL LIABILITIES Fair Value at Fair Value Measurement Using January 31, 2024 Level 1 Level 2 Level 3 Derivative liabilities $ 1,042,955 - - $ 1,042,955 Fair values of financial liabilities as of April 30, 2022, are as follows: Fair Value at Fair Value Measurement Using April 30, 2023 Level 1 Level 2 Level 3 Derivative liabilities $ 1,375,767 - - $ 1,375,767 The following is a description of the valuation methodologies used for these items: Derivative liabilities The Company did not identify any other non-recurring assets and liabilities that are required to be presented in the balance sheets at fair value following A.S.C. Topic 825, “ The Fair Value Option for Financial Issuances

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Jan. 31, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE G – PROPERTY AND EQUIPMENT Significant classes of property and equipment on January 31, 2024, and April 30, 2023, consist of the following: SCHEDULE OF PROPERTY AND EQUIPMENT January 31, 2024 April 30, 2023 Computer equipment, software and furniture $ 213,262 $ 213,262 Less: accumulated depreciation (213,262 ) (213,262 ) Net property and equipment $ - $ - All equipment is fully depreciated as of January 31, 2023, and 2022. No additional investment in equipment for both fiscal years.

WARRANTS

WARRANTS	9 Months Ended
	Jan. 31, 2024
Warrants
WARRANTS	NOTE H – WARRANTS : No warrants were issued to employees or services. As of January 31, 2024 , a total of 9,229,370 211,614

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Jan. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE I – COMMITMENTS AND CONTINGENCIES Operating Lease Commitments Our executive offices are located in New York, NY. We have an agreement for use of office space at this location under a sublease which expired on July 31, 2018, and continues on a month-to-month basis thereafter. The monthly base rent is $ 5,100 Rent expense was $ 54,000 49,700 Litigation The Company is subject to legal proceedings and claims arising in its business’s ordinary course. Sparta can make no representations about the potential outcome of such proceedings. As of January 31, 2024, we have not been named as parties to any further legal proceedings except those disclosed prior and updated below. From time to time, we may become involved in other legal proceedings, which sometimes arise due to the very nature of and in the ordinary course of this business. By way of background, the Company had received notices dated April 1, 2016, May 13, 2016, and July 22, 2016, from two lenders claiming defaults relating to conversion requests of $ 8,365.00 5,000.00 55,125.00 27,500.00 For the above claims, on September 22, 2016, a motion for summary judgment instead of complaint was filed in the Supreme Court in the State of New York: County of Kings against the Company by a lender for the amount of $ 102,170.82

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Jan. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE J – SUBSEQUENT EVENTS The Company had evaluated subsequent events for recognition and disclosure as of March 25, 2024 when the financial statements were available to be issued.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Jan. 31, 2024
Accounting Policies [Abstract]
Business	Business General Overview Sparta Commercial Services, Inc. (“Sparta,” “we,” “us,” or the “Company”) is a Nevada corporation with headquarters in New York City. We are a multi-disciplined parent corporation operating across three business sectors – Financial Services, E-Commerce & Mobile Technology, and Health and Wellness. Sparta’s historic roots were in the Powersports industry until the financial crisis that began 2008. The Company provided consumer retail installment loans and leases through authorized motorcycle dealerships in 33 states, with financing lines of credit provided by institutional lenders. In 2007, the Company introduced a Municipal Financing program which has financed over 100 jurisdictions to date. Vehicle History Reports are a staple of Sparta’s E-Commerce Technology subsidiary iMobile Solutions, Inc. Whether a vehicle is intended for personal, business or recreational use, Sparta’s Vehicle History Reports are highly regarded for accuracy and completeness and have been sold across all 50 states and in 62 countries worldwide. With iMobile App, the Company additionally provides mobile technology services, including web and mobile application creation, development and management, text messaging services, CRM (Customer Relationship Management) tools, and custom kitchen ordering systems for a wide range of businesses to increase revenue, build brand recognition, and improve customer engagement. Sparta’s subsidiary, New World Health Brands, Inc., offers high quality dietary supplements. Sparta’s subsidiary, Sparta Crypto, Inc., is in the process of completing a proprietary state-of-the-art platform designed to connect users of widely adopted digital currencies with sellers of various goods and services; and has completed and tested a cryptocurrency payment gateway called SpartaPayIQ. Agoge Global USA, Inc. (“Agoge”) was formed as a subsidiary of Sparta Crypto, Inc. in December 2022 and entered into a Joint Venture Agreement with WeDev Group of Brazil to facilitate cross-border transactions between importers and exporters of goods from the U.S. and Brazil and is expected to launch in last fiscal quarter of 2024
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements as of January 31, 2024 and for the nine months ended January 31, 2024 and 2023 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission, including Form 10-Q and Regulation S-K. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments), which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. The Company believes that the disclosures provided are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and explanatory notes for the year ended April 30, 2023 as disclosed in the Company’s Form 10-K for that year as filed with the Securities and Exchange Commission on August 15, 2023. The results of operations for the nine months ended January 31, 2024 are not necessarily indicative of the results to be expected for any other interim period or the full year ending April 30, 2024.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The third-party ownership of the Company’s subsidiary is accounted for as noncontrolling interest in the consolidated financial statements. Changes in the noncontrolling interest are reported in the statement of changes in deficit.
Estimates	Estimates These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosures of revenues and expenses for the said period. Accordingly, actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition During the first quarter of 2018, the Company adopted A.S.U. 2014-09, Revenue from Contracts with Customers (Topic 606) The Company acts as a principal in its revenue transactions as it is the primary obligor. SCHEDULE OF DISAGGREGATION REVENUE 3-months ended 9-months ended Revenue Jan 2024 Jan 2023 Jan 2024 Jan 2023 Information technology $ 30,071 $ 60,120 $ 128,142 $ 173,559 New World Health $ 6,665 $ 3,550 $ 23,291 $ 15,483 Total 36,736 63,670 151,433 189,042 Revenues from mobile app products and New World Health Brands products are generally recognized upon delivery. Revenues from History Reports are typically recognized upon delivery/download. Prepayments received from customers before delivery (if any) are recognized as deferred revenue and recognized upon delivery. The Company records deferred revenues when cash payments are received or due before our performance, including refundable amounts.
Cash Equivalents	Cash Equivalents All liquid investments with three months or less maturity are cash equivalents for the accompanying financial statements.
Fair Value Measurements	Fair Value Measurements The Company has adopted ASC 820, “Fair Value Measurements .” ● Level 1 — ● Level 2 — ● Level 3 — This hierarchy requires the Company to use observable market data when available and to minimize the use of unobservable inputs when determining fair value. Observable inputs may not always be available for some products or in certain market conditions.
Income Taxes	Income Taxes We utilize ASC 740, “ Income Taxes The Company recognizes the impact of a position in the financial statements only if that position is more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position. Our practice recognizes interest or penalties related to income tax matters in income tax expense.
Stock-Based Compensation	Stock-Based Compensation We account for our stock-based compensation under ASC 718 “ Compensation–Stock Compensation We use the fair value method for equity instruments granted to non-employees and the Black-Scholes model to measure options’ fair value. The stock-based fair value compensation is determined as of the date of the grant or at which the performance of the services is completed (measurement date) and is recognized over the vesting periods.
Inventories	Inventories The Company’s inventories represent finished goods, consisting of available products. They are accounted for using the first-in, first-out (FIFO) method and valued at the lower of cost or net realizable value. Inventory consists of finished goods for the Company’s New World Health business.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost. Minor additions and renewals are expensed in the year incurred. Significant additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is calculated using the straight-line method over the estimated useful lives. The estimated useful lives of significant depreciable assets are as follows: SCHEDULE OF ESTIMATED USEFUL OF PROPERTY AND EQUIPMENT Leasehold improvements 3 years Furniture and fixtures 7 years Website costs 3 years Computer Equipment 5 years Estimated Useful of Property and Equipment 5 years
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents, and receivables. The Company places its cash and temporary cash investments with high-credit quality institutions. At times, such investments may be more than the FDIC insurance limit.
Net Loss Per Share	Net Loss Per Share The Company uses ASC 260-10, “ Earnings Per Share
Derivative Liabilities	Derivative Liabilities The Company assessed the classification of its derivative financial instruments as of January 31, 2024, and April 30, 2024, which consist of convertible instruments and rights to shares of the Company’s common stock. It determined that such derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed conventional, as described.
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “ Accounting for Derivative Instruments and Hedging Activities The Company assessed the classification of its derivative financial instruments as of January 31, 2024 and April 30, 2023, which consist of convertible instruments and rights to shares of the Company’s common stock and determined that such derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described.
Reclassifications	Reclassifications Certain reclassifications have been made to conform with prior periods’ data to the current presentation. These reclassifications did not affect reported losses.
Recent Accounting Pronouncements-	Recent Accounting Pronouncements- No recent pronouncements have been made or adopted in the quarter ended January 31, 2024. All of the pronouncements that affect our business have been adopted.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Jan. 31, 2024
Accounting Policies [Abstract]
SCHEDULE OF DISAGGREGATION REVENUE	The Company acts as a principal in its revenue transactions as it is the primary obligor. SCHEDULE OF DISAGGREGATION REVENUE 3-months ended 9-months ended Revenue Jan 2024 Jan 2023 Jan 2024 Jan 2023 Information technology $ 30,071 $ 60,120 $ 128,142 $ 173,559 New World Health $ 6,665 $ 3,550 $ 23,291 $ 15,483 Total 36,736 63,670 151,433 189,042
SCHEDULE OF ESTIMATED USEFUL OF PROPERTY AND EQUIPMENT	SCHEDULE OF ESTIMATED USEFUL OF PROPERTY AND EQUIPMENT Leasehold improvements 3 years Furniture and fixtures 7 years Website costs 3 years Computer Equipment 5 years Estimated Useful of Property and Equipment 5 years

NOTES PAYABLE AND DERIVATIVES (

NOTES PAYABLE AND DERIVATIVES (Tables)	9 Months Ended
	Jan. 31, 2024
Debt Disclosure [Abstract]
SCHEDULE OF NOTES PAYABLE	The Company has numerous outstanding notes payable to various parties. The notes bear interest at rates of 5 20 SCHEDULE OF NOTES PAYABLE Notes Payable January 31, 2024 April 30, 2023 Notes convertible at holder’s option $ 2,313,697 $ 3,112,734 Notes convertible at Company’s option 335,700 335,700 Non-convertible notes payable 2,438,308 1,861,650 Subtotal 5,087,705 5,310,084 Total $ 5,087,705 $ 5,310,084
SCHEDULE OF DERIVATIVE LIABILITIES ASSUMPTIONS USING BLACK-SCHOLES OPTION	The change in fair value of the derivative liabilities on January 31, 2024, was calculated with the following average assumptions using a Black-Scholes option pricing model are as follows: SCHEDULE OF DERIVATIVE LIABILITIES ASSUMPTIONS USING BLACK-SCHOLES OPTION Significant Assumptions: Risk-free interest rate Ranging from 0.16 0.2 % Expected stock price volatility Ranging from 155 270 % Expected dividend payout 0 Expected life in years Ranging from 0.25 3.0 Expected life in years Ranging from 0.25 3.0
SCHEDULE OF CHANGES IN DERIVATIVE LIABILITIES	Changes in derivative liability during the three months ended January 31, 2024, and 2023 were: SCHEDULE OF CHANGES IN DERIVATIVE LIABILITIES January 31, January 31, 2024 2023 Balance, beginning of year $ 1,375,767 $ 9,549,640 Derivative liability extinguished (100,797 ) (336,418 ) Derivative financial liability arising on the issuance of convertible notes and warrants - Fair value adjustments (76,576 ) (4,168,344 ) Balance, end of period $ 1,198,394 $ 4,504,762

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Jan. 31, 2024
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUES OF FINANCIAL LIABILITIES	The table below summarizes the fair values of financial liabilities as of January 31, 2024: SCHEDULE OF FAIR VALUES OF FINANCIAL LIABILITIES Fair Value at Fair Value Measurement Using January 31, 2024 Level 1 Level 2 Level 3 Derivative liabilities $ 1,042,955 - - $ 1,042,955 Fair values of financial liabilities as of April 30, 2022, are as follows: Fair Value at Fair Value Measurement Using April 30, 2023 Level 1 Level 2 Level 3 Derivative liabilities $ 1,375,767 - - $ 1,375,767

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Jan. 31, 2024
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	Significant classes of property and equipment on January 31, 2024, and April 30, 2023, consist of the following: SCHEDULE OF PROPERTY AND EQUIPMENT January 31, 2024 April 30, 2023 Computer equipment, software and furniture $ 213,262 $ 213,262 Less: accumulated depreciation (213,262 ) (213,262 ) Net property and equipment $ - $ -

SCHEDULE OF DISAGGREGATION REVE

SCHEDULE OF DISAGGREGATION REVENUE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Product Information [Line Items]
Total	$ 36,736	$ 63,670	$ 151,433	$ 189,042
Information technology [Member]
Product Information [Line Items]
Total	30,071	60,120	128,142	173,559
New World Health [Member]
Product Information [Line Items]
Total	$ 6,665	$ 3,550	$ 23,291	$ 15,483

SCHEDULE OF ESTIMATED USEFUL OF

SCHEDULE OF ESTIMATED USEFUL OF PROPERTY AND EQUIPMENT (Details)	Jan. 31, 2024
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful of Property and Equipment	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful of Property and Equipment	7 years
Website Costs [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful of Property and Equipment	3 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful of Property and Equipment	5 years

GOING CONCERN MATTERS (Details

GOING CONCERN MATTERS (Details Narrative) - USD ($)	Jan. 31, 2024	Apr. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 66,880,291	$ 66,150,857
Working capital deficit	$ 10,301,828

SCHEDULE OF NOTES PAYABLE (Deta

SCHEDULE OF NOTES PAYABLE (Details) - USD ($)	Jan. 31, 2024	Apr. 30, 2023
Debt Instrument [Line Items]
Subtotal	$ 5,087,705	$ 5,310,084
Total	5,087,705	5,310,084
Notes Convertible at Holders Option [Member]
Debt Instrument [Line Items]
Subtotal	2,313,697	3,112,734
Notes Convertible at Companys Option [Member]
Debt Instrument [Line Items]
Subtotal	335,700	335,700
Non Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Subtotal	$ 2,438,308	$ 1,861,650
Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	5%
Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	20%

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES ASSUMPTIONS USING BLACK-SCHOLES OPTION (Details)	9 Months Ended
	Jan. 31, 2024
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected dividend payout	0.16
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected dividend payout	0.2
Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected dividend payout	155
Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected dividend payout	270
Measurement Input Dividend Payout [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected dividend payout	0
Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected life	3 months
Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected life	3 years

SCHEDULE OF CHANGES IN DERIVATI

SCHEDULE OF CHANGES IN DERIVATIVE LIABILITIES (Details) - USD ($)	9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Debt Disclosure [Abstract]
Balance, beginning of year	$ 1,375,767	$ 9,549,640
Derivative liability extinguished	(100,797)	(336,418)
Derivative financial liability arising on the issuance of convertible notes and warrants
Fair value adjustments	(76,576)	(4,168,344)
Balance, end of period	$ 1,198,394	$ 4,504,762

NOTES PAYABLE AND DERIVATIVES_2

NOTES PAYABLE AND DERIVATIVES (Details Narrative) - USD ($)	9 Months Ended
	Jan. 31, 2024	Apr. 30, 2023
Debt Instrument [Line Items]
Balance of accrued interest	$ 1,651,532	$ 1,508,934
Increase of interest expenses	$ 142,598
Minimum [Member]
Debt Instrument [Line Items]
Common stock discount rate, percentage	30%
Maximum [Member]
Debt Instrument [Line Items]
Common stock discount rate, percentage	48%

LOANS PAYABLE TO RELATED PART_2

LOANS PAYABLE TO RELATED PARTIES (Details Narrative) - USD ($)	Jan. 31, 2024	Apr. 30, 2023
Related Party Transactions [Abstract]
Loans and notes payable	$ 436,253	$ 435,753

EQUITY TRANSACTIONS (Details Na

EQUITY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended					9 Months Ended		15 Months Ended
	Jan. 31, 2024	Oct. 31, 2023	Jul. 31, 2023	Jan. 31, 2023	Jul. 31, 2022	Jan. 31, 2024	Jan. 31, 2023	Jul. 31, 2023	Apr. 30, 2023
Class of Stock [Line Items]
Preferred stock, shares designated	10,000,000					10,000,000			10,000,000
Preferred stock, par value	$ 0.001					$ 0.001			$ 0.001
Number of shares issued during period, value		$ 3,875	$ 71,878		$ 94,999
Number of shares issued services, value	$ 23,491		211,343	$ 37,595	245,381
Common stock, shares authorized	750,000,000					750,000,000			750,000,000
Common stock, par value	$ 0.001					$ 0.001			$ 0.001
Common stock, shares issued	26,141,106					26,141,106			23,045,205
Common stock, shares outstanding	26,141,106					26,141,106			23,045,205
Stocks issued as note holder incentives, value					9,940
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued during period, shares		25,000	830,906	333,939
Number of shares issued during period, value		$ 25	$ 831
Number of shares issued services, shares	151,000							1,594,960
Number of shares issued services, value	$ 151			$ 334	1,595
Sale of stock, shares							3,102,346
Sale of stock, value							$ 212,500
Stocks issued as note holder incentives, shares								60,000
Stocks issued as note holder incentives, value					$ 60
Six Accredited Investors [Member]
Class of Stock [Line Items]
Number of shares issued during period, shares						1,349,005
Number of shares issued during period, value						$ 107,000
Sale of stock, shares							2,726,036
Sale of stock, value							$ 182,500
Six Accredited Investors [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued during period, shares						1,349,005
Number of shares issued during period, value						$ 107,000
Consulting [Member]
Class of Stock [Line Items]
Number of shares issued services, shares						153,864
Number of shares issued services, value						$ 48,490
Consulting [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued services, shares						153,864	1,928,899
Number of shares issued services, value						$ 48,490	$ 282,981
Incentive Noteholders [Member]
Class of Stock [Line Items]
Number of shares issued during period, shares						75,000
Number of shares issued during period, value						$ 6,975
Incentive Noteholders [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued during period, shares						75,000
Number of shares issued during period, value						$ 6,975
Eleven Accredited Investors [Member]
Class of Stock [Line Items]
Sale of stock, shares						2,747,339
Sale of stock, value						$ 191,000
Eleven Accredited Investors [Member] | Common Stock [Member]
Class of Stock [Line Items]
Sale of stock, shares						2,747,339
Sale of stock, value						$ 191,000
Accredited Investors [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued during period, shares							330,179
Stocks issued as note holder incentives, shares							950,833
Stocks issued as note holder incentives, value							$ 83,447
Accredited Investors One [Member] | Common Stock [Member]
Class of Stock [Line Items]
Stocks issued as note holder incentives, shares							378,909
Stocks issued as note holder incentives, value							$ 35,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares designated	35,850					35,850			35,850
Preferred stock, par value	$ 100					$ 100			$ 100
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares designated	1,000					1,000
Preferred stock, liquidation and redemption value per share	$ 10,000					$ 10,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares designated	4,200,000					4,200,000			4,200,000
Preferred stock, par value	$ 0.001					$ 0.001			$ 0.001
Preferred stock, liquidation and redemption value per share	$ 1					$ 1			$ 1
Number of shares issued conversion of preferred stock, shares						60,000	1,388,376
Number of shares issued conversion of preferred stock, value						$ 10,000	$ 231,396
Series C Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued conversion of preferred stock, shares						60,000
Number of shares issued conversion of preferred stock, value						$ 10,000
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares designated	2,000,000					2,000,000			2,000,000
Preferred stock, par value	$ 0.001					$ 0.001			$ 0.001
Preferred stock, liquidation and redemption value per share	$ 1					$ 1			$ 1
Number of shares issued conversion of preferred stock, shares						536,824	564,212
Number of shares issued conversion of preferred stock, value						$ 134,206	$ 141,053
Series D Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued conversion of preferred stock, shares						536,824
Number of shares issued conversion of preferred stock, value						$ 134,206
Series C Convertible Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued conversion of preferred stock, shares							1,388,376
Series D Convertible Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued conversion of preferred stock, shares							564,212

SCHEDULE OF FAIR VALUES OF FINA

SCHEDULE OF FAIR VALUES OF FINANCIAL LIABILITIES (Details) - USD ($)	Jan. 31, 2024	Apr. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 1,042,955	$ 1,375,767
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 1,042,955	$ 1,375,767

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Jan. 31, 2024	Apr. 30, 2023
Property, Plant and Equipment [Abstract]
Computer equipment, software and furniture	$ 213,262	$ 213,262
Less: accumulated depreciation	(213,262)	(213,262)
Net property and equipment

WARRANTS (Details Narrative)

WARRANTS (Details Narrative)	Jan. 31, 2024 USD ($) shares
Warrants
Warrants vested | shares	9,229,370
Fair value adjustment of warrants | $	$ 211,614

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		4 Months Ended	9 Months Ended
	Sep. 22, 2016	Jul. 22, 2016	Jan. 31, 2024	Jan. 31, 2023
Property, Plant and Equipment [Line Items]
Rent expenses			$ 54,000	$ 49,700
Lender [Member]
Property, Plant and Equipment [Line Items]
Promissory note amount		$ 8,365
Lender claiming total amount	$ 102,170.82
Lender Two [Member]
Property, Plant and Equipment [Line Items]
Promissory note amount			27,500
Lender claiming total amount		$ 5,000
Lender One [Member]
Property, Plant and Equipment [Line Items]
Promissory note amount			55,125
Executive Office Space [Member]
Property, Plant and Equipment [Line Items]
Rent expenses			$ 5,100